Imidazopyridine derivatives as promising anti-Toxoplasma gondii agents: in vitro studies, in vivo testing, and molecular modeling analysis.

RSC Adv · 2026 · PMC13334276 · PMID 42440757

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

This treatment group exhibited a profound, highly significant reduction in cerebral cyst load of 82.68% translating to a mere 25.67 cysts on average, compared to the infected, untreated controls.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Imidazopyridine derivatives as promising anti-&lt;i&gt;Toxoplasma gondii&lt;/i&gt; agents: &lt;i&gt;in vitro&lt;/i&gt; studies, &lt;i&gt;in vivo&lt;/i&gt; testing, and molecular modeling analysis.

The sentences

Imidazopyridine derivatives as promising anti-<i>Toxoplasma gondii</i> agents: <i>in vitro</i> studies, <i>in vivo</i> testing, and molecular modeling analysis.